Both therapies improved patients’ cognition, the trial showed. But patients in the interferon beta-1b group had more relapses and brain lesions than the Gilenya-treated patients.
Overall, the results supported the notion that both therapies can improve MS patients’ cognition. But “despite a disadvantage in terms of baseline characteristics [severity of the disease] and drop-out patterns, fingolimod treatment demonstrated significantly better effects than interferon beta-1 on MRI parameters and relapse rate,” the team concluded.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?